retatrutide clinical trials status 2025 Eli Lilly infiltrates anti-obesity market as Phase III trial for begins Perceived benefits of treatment for A New Obesity Drug Delivered

However, the landmark SURMOUNT-5 trial (published in mid-2025), which compared the two medications head-to-head, clarified the clinical reality: Total Weight Loss: Tirzepatide drives significantly greater total weight loss (averaging over 20%) compared to semaglutide (averaging roughly 14%)

Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion

Kyal shares his wealth of knowledge and personal experiences, delving into how these powerful compounds can revolutionise our approach to health, especially for those of us dealing with chronic gut issues like Crohn's Disease

doi: 10.1016/j.arr.2010.02.005

Sermorelin vs CJC-1295/Ipamorelin: Side-by-Side Comparison Heres the head-to-head breakdown our patients find most useful when deciding between sermorelin vs CJC-1295/Ipamorelin : Can You Switch Between Them